Sri Lanka · Medical and donor conditions

Clinical consent-review desk with an unbranded microscope visible through glass.
Editorial illustration only; it does not depict a verified clinic or legal approval.

Sri Lanka surrogacy: medical and donor requirements

At a glance

The public clinical guidance sets out medical and donor criteria for gestational surrogacy and ART, but its legal force remains unresolved. The Ministry of Health’s Code of Practice PDF is labelled 2024; FHB lists it as Circular No. 01-42/2025, published in February 2025.

These are guidance, not proof of enforceability. Use the matrix and checklist before treatment.

What the document does—and does not—establish

The guideline itself refers to provisions in a proposed Assisted Reproductive Technology Act. A 2025 legal paper from the University of Colombo likewise describes the framework as guideline-based at the time of its analysis. A further source check found a discrepancy in official records: the Family Health Bureau’s current page lists Circular No. 01-42/2025, published in February 2025, while the Ministry of Health’s 2025 progress report says Circular No. 01-42/2024 was issued in 2024 as an interim measure (SRC-04). The materials do not establish whether the 2025 listing reissued, renumbered or superseded the 2024 circular. A report in The Sunday Times dated 18 January 2026 also quotes Supreme Court Justice Yasantha Kodagoda calling for a comprehensive legal framework and describing the lack of a specialised regulatory framework (SRC-05). That is a report of public comments, not a judgment or statute.

Do not present the guideline as legislation or assume each “must” automatically creates an offence, private claim or enforceable contract term. The absence of a dedicated ART Act does not mean surrogacy is unrestricted: general medical, contract, family, registration and child-protection law may still apply. Ask Sri Lankan counsel to verify current legislation, Gazette notices and enforceability.

The document describes FSGB and ART Authority as regulatory structures and PHSRC as the interim registration/supervision body. Their current operation and the clinic’s registration remain unverified; obtain written confirmation from the competent authority.

Medical indication and surrogate age

Section 5.15 limits gestational surrogacy to medical reasons: carrying a pregnancy to term must be physically or medically impossible or undesirable for the patient. The specialist should assess the case and the clinic should record the criteria supporting the surrogate’s fitness for a full-term pregnancy.

A surrogate should not be over 45; this is separate from the ART-treatment age rule and from any egg-donor exception. A relative, another known person or someone unknown to the intended parents may act as surrogate. For a relative, being from the same generation as the intended mother is described as ideal, not mandatory.

Fitness, infection screening and previous surrogacy

Before acceptance, the clinic should document the surrogate’s health, fitness for a full-term pregnancy and relevant obstetric or medical risks. The specialist should counsel the surrogate and her husband about pregnancy risks; this section does not equate counselling with the husband’s legal consent.

Immediately before embryo transfer, the surrogate must test negative for HIV, syphilis and hepatitis B/C and should be immune to rubella. The guideline says no woman may act as a surrogate more than three times in her lifetime. Ask the clinic to confirm accepted test dates, rubella evidence and obstetric history. If a result is positive, missing or out of date, pause for a specialist’s written assessment rather than assuming it can be waived.

Patient eligibility, age and written consent

For women receiving medically assisted reproduction (MAR/ART), the guideline says treatment should not be provided beyond age 50 and no embryo transfer should take place after the woman’s 50th birthday. This is not the surrogate’s age rule: the surrogacy section separately sets the “not over 45” criterion for the surrogate.

For Sri Lankan citizens receiving MAR/ART, the document says legal marriage is mandatory and that the clinic should keep true copies of the couple’s marriage certificate and identity documents. It says foreign citizens who are legally married, in a civil partnership or in a stable relationship can be offered treatment. That wording is not a guarantee of access to a surrogacy programme, a ruling on foreign intended-parent eligibility, or a decision about parentage after birth.

Before IVF, the clinician must assess and record the wellbeing of the unborn child; treatment may be refused or FSGB advice sought if concerns remain after consultation. The guideline requires informed written consent from both partners for ovarian stimulation and IVF/ICSI fertilisation (including donor gametes), separate consent for egg retrieval, and consent specifying the storage period for frozen gametes or embryos. For embryo donation, both biological parents who donate the embryo must consent in writing; recipient treatment consents are separate.

Donor registration and medical assessment

Sperm, oocyte and embryo donors should be registered with the FSGB. Centres should keep donor registers and report cycles quarterly. Before registration, a qualified specialist or medical officer should assess significant medical/genetic conditions and infection risks.

After a foetal/congenital anomaly or other genetically related adverse pregnancy outcome, the guidance calls for donor reassessment and withholding that donor’s gametes pending FSGB clearance. Because the document describes some oversight bodies as proposed, verify who currently maintains the register, what proves registration and how adverse outcomes are handled.

For donor embryos, the guidance requires written consent from both biological parents before use; describes donation as voluntary and non-commercial; requires traceability to the biological parents or the couple whose gametes were used; and says centres should not profit from supplying surplus embryos or create embryos from donor gametes for commercial gain without an identified recipient. Confirm the current clinic protocol and records; do not assume each provision is independently enforceable law.

Sperm donor criteria

The guideline sets out a maximum of 10 children through sperm-donation cycles for one donor. It calls for screening for HIV 1 and 2, hepatitis B and C, and syphilis, with negative results before the sample is obtained and repeat testing after a three-month window period before the sample is used. The donor’s blood group should be disclosed to the recipient and explained. Non-identifying donor characteristics may be shared, while identity should remain confidential unless disclosure is required by law.

The recommended sperm-donor age is 20–45; an older donor may be considered exceptionally if no suitable younger donor is available, after assessment and counselling. Donors should not have significant medical or inherited illnesses that could risk the recipient or child. The guidance recommends anonymous donation through a licensed centre and discourages known-donor arrangements. It states that an anonymous donor at a licensed centre is not the child’s legal parent, has no parental responsibilities, is not named on the birth certificate and owes no financial support. For private donation, it says the clinic does not take responsibility for legal parenthood and that the woman who gives birth is the legal mother. These are guidance statements, not a verified ruling on current law; do not merge private donation with the separate surrogacy parentage process.

Egg donor criteria and egg sharing

For oocyte donors, the guideline says a donor should be removed from the register after the donor has contributed to the birth of 10 children through oocyte-donation cycles. It also sets a maximum of four egg-donation cycles for one donor and a minimum six-month gap between consecutive cycles. HIV 1 and 2, syphilis, hepatitis B and C screening should show negative results within the three months before donation. Donor identity should remain confidential unless disclosure is required by law.

The ideal egg-donor age is over 20 and under 35; an older donor may be considered exceptionally if no suitable younger donor is available. Donors should not have significant medical or inherited illnesses. Having a living child is preferred, not an absolute condition. Egg-sharing participants are generally 20–35, may have children or not, and must be medically suitable; the centre sets the recipient’s contribution to the donor’s IVF costs up to retrieval. The consultant and centre are responsible for donor safety and care for ART complications. Obtain the clinic’s written cost and follow-up policies.

Payments: a point that needs written clarification

The guidance treats commercial egg, sperm or embryo donation as inappropriate and says a fertility centre shall not obtain gametes on a commercial basis. The embryo-donation section elsewhere only says commercial donation is discouraged, so the document’s wording is not fully consistent. It permits reimbursement of actual expenses (travel, meals/accommodation, dependent care, counselling/legal services, medicines, clinic services, health costs and records). The detailed text sets caps of LKR 150,000 per egg donation and LKR 10,000 per sperm donation, with FSGB approval said to be required above the caps. It does not clearly explain whether or how these limits apply to embryo donation; do not extrapolate them.

Section 5.10.6(H) also says a sperm donor may receive “reasonable compensation” per cycle as recommended by the FSGB, without reconciling that phrase with expense reimbursement and the stated caps. Do not infer legality or illegality from this inconsistency alone. Before payment, obtain written clarification from the clinic/current authority, an itemised expense basis and any approval relied upon.

Surrogate payments are separate: section 5.15 says they should cover genuine pregnancy-related expenses and be documented. This does not settle compensation or contract enforceability.

Practical decision matrix

IssueWhat the guidance saysWhat to verify before proceeding
SurrogateMedical indication; age not over 45; fitness recorded; HIV, syphilis, hepatitis B/C negative just before transfer; rubella immunity; no more than three lifetime surrogacies.Specialist report, dated lab results, rubella evidence, obstetric history and prior-surrogacy declaration.
Patient receiving ARTNo embryo transfer after the 50th birthday; separate civil-status rules for Sri Lankan and foreign citizens; informed written consents.Identity and status documents, clinic’s eligibility decision and signed procedure/storage consents.
Sperm donorRecommended age 20–45; STI tests plus repeat after three months; maximum 10 children; identity confidentiality subject to law.Screening dates, donor register/offspring count, donor consent and written anonymity policy.
Egg donorIdeal age over 20 and under 35; maximum four cycles with six months between; maximum 10 children; negative infection screen within three months.Medical/genetic assessment, test dates, cycle history, offspring count and consent.
Payments and clinicDonor expense caps and a conflicting sperm-compensation sentence; clinic registration/authority requires confirmation.Itemised costs, written regulator clarification, current registration number and proof of its scope.
Embryo donationWritten consent from both biological parents; donation should be voluntary; commercial donation is discouraged; traceability; centre should not profit from supplying surplus embryos.Signed donor consents, embryo origin and traceability records, identified recipient, and itemised centre charges.

This matrix summarises guidance, not law; preserve “recommended”, “ideal” and “should” qualifications.

Documents and questions to obtain in writing

Before paying, signing or authorising embryo transfer, request a written, case-specific file. At minimum, ask for:

  • the current version of the Ministry guidance and the clinic’s own protocol, with any additional clinic criteria clearly identified as clinic policy;
  • the clinic’s current registration/licence number, issuing authority, validity period and confirmation that the registration covers the proposed fertility procedures;
  • the specialist’s written medical-indication and fitness assessment for surrogacy, relevant obstetric history, prior-surrogacy history, dated infection results and evidence of rubella immunity;
  • identity and civil-status documents required for the intended patients, plus the informed written consents for stimulation, fertilisation, egg retrieval, freezing/storage and the agreed storage period;
  • the donor’s consent, screening results, relevant donor-register evidence, prior cycle/offspring count and the clinic’s written explanation of confidentiality and any lawful disclosure exception;
  • an itemised payment schedule distinguishing clinic fees, genuine surrogate pregnancy expenses, donor expense reimbursement and any proposed compensation; request receipts and the written authority for any payment above a stated cap;
  • the legal route proposed for establishing parentage after birth, including the documents and competent authority involved. Obtain independent Sri Lankan legal advice on this separate question.

The guideline includes sperm-donation and IVF/ICSI consent/storage forms; confirm current versions. Forms alone do not resolve parentage.

When to pause the programme

Pause before embryo transfer if the clinic cannot show current registration, identify the competent regulator, document medical indication and surrogate fitness, provide current screening, evidence donor assessment/consent, or reconcile donor cycles and offspring counts.

Also pause if payments ignore the stated caps, rely on the ambiguous “reasonable compensation” wording without written authority, or promise a guaranteed legal outcome. Ask the clinic to identify whether each requirement comes from law, official guidance or clinic policy. A stricter clinic policy may affect acceptance but is not automatically nationwide law; positive or incomplete tests require medical review, not a legal workaround.

Bottom line and scope limits

Use the matrix as a pre-treatment checklist, not proof of legal approval. Before payment or embryo transfer, verify the current circular and authority, clinic registration/scope, written medical-indication and fitness evidence, dated screening, donor consents/traceability, and payment basis. Obtain separate advice on parentage and post-birth documents.

The reviewed material does not resolve parentage, birth registration, nationality, travel documents or recognition abroad; obtain separate Sri Lankan legal advice before treatment.

Sources and review limits

  1. [SRC-01] Code of Practice and Guidelines for Medically Assisted Reproductive Techniques (Ministry of Health, Sri Lanka; PDF labelled 2024)

    Official Ministry of Health guideline PDF. Relevant sections: 5.1–5.5, 5.10 and 5.15.

  2. [SRC-02] Code of practice and guidelines for centres practicing medically assisted reproductive techniques including assisted reproductive technology — Family Health Bureau resource page

    Official Family Health Bureau resource page; identifies Circular No. 01-42/2025 and February 2025 publication.

  3. [SRC-03] Abeyrathna, D. (2025), Ethical and legal implications of Sri Lanka’s guideline-based approach to assisted reproductive technologies — University of Colombo repository

    University of Colombo legal-academic paper (2025); scholarly analysis, not legislation or a binding judgment.

  4. [SRC-04] Ministry of Health and Mass Media, Performance and Progress Report 2025 (Family Planning programme, p. 116)

    Official Ministry of Health and Mass Media progress report (2025), Family Planning programme, p. 116. It says Circular No. 01-42/2024 was issued in 2024 as an interim measure. This conflicts with the current FHB listing as 01-42/2025; the report does not explain the relationship between the two references.

  5. [SRC-05] Spotlight on the surrogate mother — The Sunday Times, 18 January 2026

    The Sunday Times report dated 18 January 2026 quotes Supreme Court Justice Yasantha Kodagoda’s public call for a comprehensive legal framework and describes the lack of specialised regulation. It reports public remarks; it is not a judgment or statute.

Last updated:

Author: Khachatrian Razmik, LL.M.

International surrogacy and parentage legal services — LEX SURROGACY by Lex Agency · Author profile · Editorial standards